1. Home
  2. CBIO vs WILC Comparison

CBIO vs WILC Comparison

Compare CBIO & WILC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CBIO
  • WILC
  • Stock Information
  • Founded
  • CBIO 2003
  • WILC 1994
  • Country
  • CBIO United States
  • WILC Israel
  • Employees
  • CBIO N/A
  • WILC N/A
  • Industry
  • CBIO
  • WILC Food Distributors
  • Sector
  • CBIO
  • WILC Consumer Discretionary
  • Exchange
  • CBIO Nasdaq
  • WILC Nasdaq
  • Market Cap
  • CBIO 308.0M
  • WILC 287.1M
  • IPO Year
  • CBIO N/A
  • WILC 1997
  • Fundamental
  • Price
  • CBIO $14.29
  • WILC $20.49
  • Analyst Decision
  • CBIO Strong Buy
  • WILC
  • Analyst Count
  • CBIO 5
  • WILC 0
  • Target Price
  • CBIO $25.60
  • WILC N/A
  • AVG Volume (30 Days)
  • CBIO 97.6K
  • WILC 13.9K
  • Earning Date
  • CBIO 07-31-2025
  • WILC 08-12-2025
  • Dividend Yield
  • CBIO N/A
  • WILC 4.81%
  • EPS Growth
  • CBIO N/A
  • WILC 130.51
  • EPS
  • CBIO N/A
  • WILC 2.04
  • Revenue
  • CBIO N/A
  • WILC $177,609,889.00
  • Revenue This Year
  • CBIO N/A
  • WILC N/A
  • Revenue Next Year
  • CBIO N/A
  • WILC N/A
  • P/E Ratio
  • CBIO N/A
  • WILC $9.93
  • Revenue Growth
  • CBIO N/A
  • WILC 9.73
  • 52 Week Low
  • CBIO $10.83
  • WILC $9.55
  • 52 Week High
  • CBIO $21.40
  • WILC $22.85
  • Technical
  • Relative Strength Index (RSI)
  • CBIO 52.92
  • WILC 43.32
  • Support Level
  • CBIO $13.50
  • WILC $20.20
  • Resistance Level
  • CBIO $16.00
  • WILC $21.25
  • Average True Range (ATR)
  • CBIO 0.79
  • WILC 0.68
  • MACD
  • CBIO 0.16
  • WILC -0.23
  • Stochastic Oscillator
  • CBIO 39.68
  • WILC 13.49

About CBIO Crescent Biopharma Inc. Common Stock

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

About WILC G. Willi-Food International Ltd.

G. Willi-Food International Ltd is a company engaged in high-quality, great-tasting kosher food products. The Company is engaged, directly and through subsidiaries, with one segment Import-export, marketing, and distribution of food products. The principal product line includes Canned Vegetables and Pickles, Canned Fish, Canned Fruit, Edible Oils, Dairy and Dairy Substitute Products, Dried Fruit, Nuts and Beans, and Other Products. Its brands include Willi-Food, Euro European Dairies, Donna Rozza, Manchow, Gold Frost, Tifeeret, The Chef Dish, Art Coffe, Mr. Chang, Muchi, Euro Butter, Euro Spread, Euro Cheese, Euro Cream, Euro Dessert, Euro Veg, Ha-Bulgaria, Gelato, and Emma.

Share on Social Networks: